First clinical comparison of Nobori –Biolimus A9 eluting stents with Cypher– Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes

Ostojić, Miodrag; Sagić, Dragan; Beleslin, Branko; Jung, Robert; Perišić, Zoran; Jagić, Nikola; Nedeljković, Milan; Mangovski, Ljupco; Milosavljevic, Bratislav; Stojković, Siniša; Orlić, Dejan; Antonić, Želimir; Miloradović, Vladimir; Topic, Dragan; Paunovic, Dragica

doi:10.4244/eijv3i5a103

Cited by 62 publications

(43 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In several randomized trials, the BES showed fairly similar angiographic outcomes to those of the sirolimus-eluting stent, with comparable clinical outcomes. 20,21 In those trials, in-stent late loss at the 9-month angiographic follow-up was between 0.10 and 0.12 mm for a relatively short lesion length. However, the current LONG-DES V trial showed an in-stent late loss of 0.20 mm for lesions with a mean length of 30 mm.…”

Section: Discussionmentioning

confidence: 99%

Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions

Lee

Park

Kim

et al. 2014

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

Background-Procedural and clinical outcomes still remain unfavorable for patients with long coronary lesions who undergo percutaneous coronary intervention. The current study, therefore, evaluated 2 innovative drug-eluting stents for the management of long-lesion coronary artery disease. Methods and Results-This randomized, multicenter, prospective trial, called the Long Drug-Eluting Stent (LONG-DES) V trial, compared the biodegradable polymer-based biolimus A9-eluting stent (BES) and the durable polymer-based platinum chromium everolimus-eluting stent (PtCr-EES) in 500 patients with long (≥25 mm) coronary lesions. The primary end point of the trial was in-segment late luminal loss at the 9-month angiographic follow-up.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions

Lee

Park

Kim

et al. 2014

Circ: Cardiovascular Interventions

View full text Add to dashboard Cite

show abstract

“…11 The Nobori biolimus-eluting stent is a stainless steel platform loaded with polylactic acid as a polymer eluting biolimus A9, a highly lipophilic analog of sirolimus, and there is a bioabsorbable polymer only on the abluminal side. 12 Meta-analysis has demonstrated that the use of the Nobori biolimus-eluting stent is associated with a similar safety and efficacy as permanent polymer DES at 1-year follow-up, albeit it is superior to paclitaxel-eluting stents in terms of target lesion revascularization rates. 13 In addition, of the next generation DES, the Nobori biolimus-eluting stent demonstrated a lower inflammatory response in the stented segment compared with the SES in a porcine coronary artery model.…”

Section: Disclosuresmentioning

confidence: 99%

Impact of Insulin Resistance on Clinical Outcomes After Implantation of Drug-Eluting Stents

Miyata

2016

Circ J

View full text Add to dashboard Cite

Circulation Journal Official Journal of the Japanese Circulation Society http://www. j-circ.or.jp or failed cellular response to insulin receptor-activated signaling in insulin-sensitive tissues such as the liver, skeletal muscle, adipose, and brain, which results in reduced glucose uptake by these tissues and concomitant increase in hepatic glucose output, both leading to elevated plasma glucose concentrations. The subsequent change in glucose homeostasis places an increased burden on pancreatic β-cells to produce and secrete more insulin in order to restore normal blood carbohydrate levels. 4 The hyperinsulinemia upregulates glucose transport, glycogen synthesis, gluconeogenesis, lipolysis, protein synthesis, proliferation, differentiation, and inflammation. 5 Uetani et al have reported the effect of IR on post-procedural myocardial injury and clinical outcomes after elective PCI with DES deployment. 6 The incidence of late and very late stent thrombosis increases after implantation of 1st-generation DES, in which delayed arterial healing and poor re-endothelialization may play a major role. 7 In addition, late incomplete stent apposition was observed in 8.7% of patients after implantation of a sirolimuseluting stent (SES), a 1st-generation DES. 8 An autopsy case ercutaneous coronary intervention (PCI) using drugeluting stents (DES) is a widespread and efficacious treatment for coronary artery disease, and has dramatically reduced the incidence of restenosis after PCI compared with bare-metal stents or balloon angioplasty. However, stent thrombosis and the late catch-up phenomenon are major problems of DES implantation. In this issue of the Journal, Komatsu et al analyze 109 patients who underwent elective PCI and implantation of 1st-generation DES and demonstrated that insulin resistance (IR) was associated with the late catchup phenomenon after DES implantation. 1 These findings are clinically interesting and evaluation of IR may provide useful information for predicting clinical outcomes after DES implantation. Article p 657IR is a key pathological factor of the metabolic syndrome, and associated with the risk of diabetes mellitus, microalbuminuria, 2 and cardiovascular events. 3 IR refers to an impaired Impact of Insulin Resistance on Clinical Outcomes After Implantation of Drug-Eluting StentsMasaaki Miyata, MD, PhD Figure. Insulin resistance, inflammation, and late catch-up phenomenon after drug-eluting stent (DES) implantation. Insulin resistance progresses the inflammation at the DES site and increases the incidence of the late catch-up phenomenon.

show abstract

“…In the following paragraphs we will review and summarize the main findings from published randomized data of the Limus Eluted from a Durable vs Erodable Stent Coating (LEADERS) [28] , NOBORI [33,34] , Individualized Drug Eluting Stent System to Abrogate Restenosis (ISAR)-TEST-3 [35] and TEST-4 [36,37] with sirolimus (rapamycin), PAINT (percutaneous intervention with BIO-polymer based paclitaxel-eluting or sirolimus-eluting vs bare stents for de novo coronary lesions) [38] and EUCATAX [39] trials. Study and stent design of each trial is described in Table 1.…”

Section: Technologymentioning

confidence: 99%

“…Two years follow-up of this trial was recently pre- [34] PLA Stainless-steel S-stent Biolimus 15.6 9-12 mo Two phases: immediately after stent implantation; sustained drug release over 9-12 mo NOBORI CORE [33] PLA Stainless-steel S-stent Biolimus 15.6 9-12 mo Two phases: immediately after stent implantation; sustained drug release over 9-12 mo LEADERS [28] PLA sented [37] , and a sustained equivalence in the incidence of safety/efficacy end points between BIO and permanent polymer DES designs was seen. The incidence of stent thrombosis was similar in both study arms.…”

Section: Isar-test-4 Trialmentioning

confidence: 99%

See 1 more Smart Citation

Advantages and disadvantages of biodegradable platforms in drug eluting stents

Rodriguez-Granillo

Rubilar²,

Rodríguez-Granillo³

et al. 2011

WJC

View full text Add to dashboard Cite

Coronary angioplasty with drug-eluting stent (DES) implantation is currently the most common stent procedure worldwide. Since the introduction of DES, coronary restenosis as well as the incidence of target vessel and target lesion revascularization have been significantly reduced. However, the incidence of very late stent thrombosis beyond the first year after stent deployment has more commonly been linked to DES than to baremetal stent (BMS) implantation. Several factors have been associated with very late stent thrombosis after DES implantation, such as delayed healing, inflammation, stent mal-apposition and endothelial dysfunction. Some of these adverse events were associated with the presence of durable polymers, which were essential to allow the elution of the immunosuppressive drug in the first DES designs. The introduction of erodable polymers in DES technology has provided the potential to complete the degradation of the polymer simultaneously or immediately after the release of the immunosuppressive drug, after which a BMS remains in place.Several DES designs with biodegradable (BIO) polymers have been introduced in preclinical and clinical studies, including randomized trials. In this review, we analyze the clinical results from 6 observational and randomized studies with BIO polymers and discuss advantages and disadvantages of this new technology.

show abstract

First clinical comparison of Nobori –Biolimus A9 eluting stents with Cypher– Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes

Cited by 62 publications

References 14 publications

Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions

Comparison of Biolimus A9–Eluting (Nobori) and Everolimus-Eluting (Promus Element) Stents in Patients With De Novo Native Long Coronary Artery Lesions

Impact of Insulin Resistance on Clinical Outcomes After Implantation of Drug-Eluting Stents

Advantages and disadvantages of biodegradable platforms in drug eluting stents

Contact Info

Product

Resources

About